Information on EC 6.3.2.10 - UDP-N-acetylmuramoyl-tripeptide-D-alanyl-D-alanine ligase

for references in articles please use BRENDA:EC6.3.2.10
Word Map on EC 6.3.2.10
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY hide
6.3.2.10
-
RECOMMENDED NAME
GeneOntology No.
UDP-N-acetylmuramoyl-tripeptide-D-alanyl-D-alanine ligase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
ATP + UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-L-lysine + D-alanyl-D-alanine = ADP + phosphate + UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-L-lysyl-D-alanyl-D-alanine
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
carboxamide formation
carboxylic acid amide formation
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
UDP-N-acetylmuramoyl-pentapeptide biosynthesis I (meso-diaminopimelate containing)
-
-
UDP-N-acetylmuramoyl-pentapeptide biosynthesis II (lysine-containing)
-
-
UDP-N-acetylmuramoyl-pentapeptide biosynthesis III (meso-diaminopimelate containing)
-
-
peptidoglycan biosynthesis
-
-
Lysine biosynthesis
-
-
Peptidoglycan biosynthesis
-
-
Metabolic pathways
-
-
SYSTEMATIC NAME
IUBMB Comments
UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysine:D-alanyl-D-alanine ligase (ADP-forming)
Involved with EC 6.3.2.4 (D-alanine---D-alanine ligase), EC 6.3.2.7 (UDP-N-acetylmuramoyl-L-alanyl-D-glutamate---L-lysine ligase) or EC 6.3.2.13 (UDP-N-acetylmuramoyl-L-alanyl-D-glutamate---2,6-diaminopimelate ligase), EC 6.3.2.8 (UDP-N-acetylmuramate---L-alanine ligase) and EC 6.3.2.9 (UDP-N-acetylmuramoyl-L-alanine---D-glutamate ligase) in the synthesis of a cell-wall peptide (click here) for diagram. This enzyme also catalyses the reaction when the C-terminal residue of the tripeptide is meso-2,4-diaminoheptanedioate (acylated at its L-centre), linking the D-Ala-D-Ala to the carboxy group of the L-centre. This activity was previously attributed to EC 6.3.2.15, which has since been deleted.
CAS REGISTRY NUMBER
COMMENTARY hide
9023-60-3
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
9602
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
metabolism
physiological function
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
ATP + UDP-N-acetylmuramoyl-L-Ala-D-Glu-L-Lys + D-Ala-D-Ala
?
show the reaction diagram
ATP + UDP-N-acetylmuramoyl-L-Ala-D-Glu-L-Lys + D-Ala-D-Ala
ADP + phosphate + UDP-N-acetylmuramoyl-L-Ala-D-Glu-L-Lys-D-Ala-D-Ala
show the reaction diagram
ATP + UDP-N-acetylmuramoyl-L-Ala-D-Glu-L-Lys + D-Ala-D-Lac
ADP + phosphate + UDP-N-acetylmuramoyl-L-Ala-D-Glu-L-Lys-D-Ala-D-Lac
show the reaction diagram
-
-
-
-
?
ATP + UDP-N-acetylmuramoyl-L-Ala-D-Glu-L-Lys + fluoro-D-Ala-fluoro-D-Ala
ADP + phosphate + UDP-N-acetylmuramoyl-L-Ala-D-Glu-L-Lys-fluoro-D-Ala-fluoro-D-Ala
show the reaction diagram
-
-
-
-
ATP + UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-diaminopimelic acid + D-alanyl-D-alanine
ADP + phosphate + UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-diaminopimeloyl-D-alanyl-D-alanine
show the reaction diagram
-
-
-
-
?
ATP + UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-L-lysine + D-alanyl-D-alanine
ADP + phosphate + UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-L-lysyl-D-alanyl-D-alanine
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
ATP + UDP-N-acetylmuramoyl-L-Ala-D-Glu-L-Lys + D-Ala-D-Ala
?
show the reaction diagram
ATP + UDP-N-acetylmuramoyl-L-Ala-D-Glu-L-Lys + D-Ala-D-Ala
ADP + phosphate + UDP-N-acetylmuramoyl-L-Ala-D-Glu-L-Lys-D-Ala-D-Ala
show the reaction diagram
ATP + UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-L-lysine + D-alanyl-D-alanine
ADP + phosphate + UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-L-lysyl-D-alanyl-D-alanine
show the reaction diagram
additional information
?
-
P11880
the specific activity of the mutant enzyme is highly reduced compared to the wild-type murF
-
?
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2R,4R)-4-(3,7-dimethoxynaphthalen-2-yl)-1-(dimethylamino)-3,4-diphenylbutan-2-ol
-
modest activity against lipopolysaccharide-defective Escherichia coli and wild-type Escherichia coli rendered permeable with polymyxin B nonapeptide. Treatment of lipopolysaccharide-defective Escherichia coli cells with >2fold minimal inhibitory concentrations of DQ1 results in a 75-fold-greater accumulation of the MurF substrate compared to the control, a 70% decline in the amount of the MurF product, and eventual cell lysis, consistent with the inhibition of MurF within bacteria
(2S,4R)-4-(3,7-dimethoxynaphthalen-2-yl)-1-(dimethylamino)-3,4-diphenylbutan-2-ol
-
additionally active against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus isolates and vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium isolates
1,4-diaminoanthra-9,10-quinone
-
pIC50 predicted by comparative residue interaction analysis: 5.0, pIC50 predicted by comparative molecular field analysis:5.5
1-(azepan-1-ylmethyl)-2-naphthol
-
pIC50 predicted by comparative residue interaction analysis: 5.7, pIC50 predicted by comparative molecular field analysis: 5.9
1-(cyclohexylmethyl)piperazine
-
pIC50 predicted by comparative residue interaction analysis: 5.5, pIC50 predicted by comparative molecular field analysis: 6.2
1-[[(4-trifluoromethylphenyl)sulfonyl]amino]-3-(morpholin-4-yl)propan-2-yl dihydrogen phosphate
-
-
2,4-dichloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-5-(morpholin-4-ylsulfonyl)benzamide
-
-
2,4-dichloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-5-[(diethylamino)sulfonyl]benzamide
-
-
2,4-dichloro-N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-5-(morpholin-4-ylsulfonyl)benzamide
-
-
2,4-dichloro-N-(3-cyano-6-phenyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-[(2-methoxyethyl)(methyl)sulfamoyl]benzamide
-
-
2,4-dichloro-N-[3-cyano-6-(4-hydroxyphenyl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]-5-(diethylsulfamoyl)benzamide
-
-
2,4-dichloro-N-[3-cyano-6-(4-hydroxyphenyl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]-5-(morpholin-4-ylsulfonyl)benzamide
-
-
2-(4-methylphenyl)pyrrolo[2,1-a]isoquinoline
-
pIC50 predicted by comparative residue interaction analysis: 5.1, pIC50 predicted by comparative molecular field analysis: 5.6
2-(propylamino)ethyl 4-amino-3-propoxybenzoate
-
-
2-([[2-chloro-5-(diethylsulfamoyl)phenyl]carbonyl]amino)-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thiophene-3-carboxamide
-
-
2-bromo-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-5-(morpholin-4-ylsulfonyl)benzamide
-
-
2-chloro-N-(3-cyano-2-thienyl)-5-[(diethylamino)sulfonyl]benzamide
-
-
2-chloro-N-(3-cyano-3,4,5,6-tetrahydro-2H-cyclopenta[b]thiophen-2-yl)-5-[(4-hydroxybutyl)sulfamoyl]benzamide
-
-
2-chloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-4-fluoro-5-(morpholin-4-ylsulfonyl)benzamide
-
-
2-chloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-5-(morpholin-4-ylsulfonyl)benzamide
-
-
2-chloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-5-[(diethylamino)sulfonyl]benzamide
-
-
2-chloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-5-[(methylamino)sulfonyl]benzamide
-
-
2-chloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-5-[[(3-hydroxypropyl)amino]sulfonyl]benzamide
-
-
2-chloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thiophen-2-yl)-4-(methylamino)-5-(morpholin-4-ylsulfonyl)benzamide
-
-
2-chloro-N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-5-(morpholin-4-ylsulfonyl)benzamide
-
-
2-chloro-N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-(diethylsulfamoyl)benzamide
-
-
2-chloro-N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-(piperidin-1-ylsulfonyl)benzamide
-
-
2-chloro-N-(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)-5-(diethylsulfamoyl)benzamide
-
-
2-chloro-N-(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)-5-(morpholin-4-ylsulfonyl)benzamide
-
-
2-chloro-N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thien-2-yl)-5-[(diethylamino)sulfonyl]benzamide
-
-
2-chloro-N-[3-cyano-5-(2-pyridin-2-ylethyl)thiophen-2-yl]-5-(morpholin-4-ylsulfonyl)benzamide
-
-
2-chloro-N-[3-cyano-6-(4-hydroxyphenyl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]-5-(diethylsulfamoyl)benzamide
-
-
2-thioxo-3-[4-(trifluoromethoxy)phenyl]-2,3-dihydroquinazolin-4(1H)-one
-
-
3-anilinocyclohex-2-en-1-one
-
pIC50 predicted by comparative residue interaction analysis: 5.2, pIC50 predicted by comparative molecular field analysis: 5.5
3-imino-3,4-dihydroisoquinolin-1(2H)-one
-
pIC50 predicted by comparative residue interaction analysis: 5.2, pIC50 predicted by comparative molecular field analysis: 5.6
4,6-dimethyl-1-[[(1E)-phenylmethylene]amino]pyridin-2(1H)-one
-
pIC50 predicted by comparative residue interaction analysis: 5.1, pIC50 predicted by comparative molecular field analysis: 4.6
4-(4-methylpiperazin-1-yl)aniline
-
pIC50 predicted by comparative residue interaction analysis: 5.7, pIC50 predicted by comparative molecular field analysis: 6.1
4-[(pentachlorobenzyl)sulfanyl]-6-sulfanyl-1,3,5-triazin-2-ol
-
i.e. NSC 209931, inhibitor identified by structure-based virtual screening
5-(aminosulfonyl)-2-chloro-N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thien-2-yl)benzamide
-
-
5-(anilinosulfonyl)-2-chloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)benzamide
-
-
6-piperazin-1-yl-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
pIC50 predicted by comparative residue interaction analysis: 5.4, pIC50 predicted by comparative molecular field analysis: 5.8
acetate
-
inhibition of wild-type enzyme
Butylamine
-
inhibition of wild-type and mutant K202A; inhibition of wild-type enzyme
Butyrate
-
slight inhibition of wild-type enzyme
ethyl 2-([[2-chloro-5-(diethylsulfamoyl)phenyl]carbonyl]amino)-3-cyano-4,5,6,7-tetrahydro-1-benzothiophene-6-carboxylate
-
-
ethylamine
-
inhibition of wild-type enzyme
formate
-
inhibition of wild-type enzyme
methylamine
-
inhibition of wild-type enzyme
N-(3-aminopropyl)-4-(trifluoromethyl)-2-([4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]methyl)pyrimidine-5-carboxamide
-
-
N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thiophen-2-yl)-2-[[3-(dimethylamino)propyl]amino]-5-(morpholin-4-ylsulfonyl)benzamide
-
-
N-(4-carbamimidoylphenyl)-4-(trifluoromethyl)-2-([4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]methyl)pyrimidine-5-carboxamide
-
-
N-(5-bromo-3-cyano-2-thienyl)-2-chloro-5-[(diethylamino)sulfonyl]benzamide
-
-
N-[3-(cyclopentylamino)propyl]-2-[[4-(4-methylphenyl)-1,3-thiazol-2-yl]amino]-4-(trifluoromethyl)pyrimidine-5-carboxamide
-
-
propionate
-
inhibition of wild-type enzyme
Propylamine
-
inhibition of wild-type enzyme
additional information
-
design of inhibitors of the MurF enzyme of Streptococcus pneumoniae using docking, 3D-QSAR, and de dovo design
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
acetate
-
activation of mutant K202A
Butyrate
-
activation of mutant K202A
ethylamine
-
slight activation of mutant K202A
formate
-
slight activation of mutant K202A
propionate
-
strong activation of mutant K202A
Propylamine
-
slight activation of mutant K202A
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
additional information
additional information
-
-
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.024
(2R,4R)-4-(3,7-dimethoxynaphthalen-2-yl)-1-(dimethylamino)-3,4-diphenylbutan-2-ol
Escherichia coli
-
-
0.15
1-[[(4-trifluoromethylphenyl)sulfonyl]amino]-3-(morpholin-4-yl)propan-2-yl dihydrogen phosphate
Escherichia coli
-
pH 8.0
0.000000302
2,4-dichloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-5-(morpholin-4-ylsulfonyl)benzamide
Streptococcus pneumoniae
-
-
0.0000052
2,4-dichloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-5-[(diethylamino)sulfonyl]benzamide
Streptococcus pneumoniae
-
-
0.001
2,4-dichloro-N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-5-(morpholin-4-ylsulfonyl)benzamide
Streptococcus pneumoniae
-
-
0.000000071
2,4-dichloro-N-(3-cyano-6-phenyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-[(2-methoxyethyl)(methyl)sulfamoyl]benzamide
Streptococcus pneumoniae
-
-
0.000000068
2,4-dichloro-N-[3-cyano-6-(4-hydroxyphenyl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]-5-(diethylsulfamoyl)benzamide
Streptococcus pneumoniae
-
-
0.000000022
2,4-dichloro-N-[3-cyano-6-(4-hydroxyphenyl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]-5-(morpholin-4-ylsulfonyl)benzamide
Streptococcus pneumoniae
-
-
0.03
2-(propylamino)ethyl 4-amino-3-propoxybenzoate
Streptococcus pneumoniae
-
-
0.000066
2-([[2-chloro-5-(diethylsulfamoyl)phenyl]carbonyl]amino)-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thiophene-3-carboxamide
Streptococcus pneumoniae
-
-
0.00000417
2-bromo-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-5-(morpholin-4-ylsulfonyl)benzamide
Streptococcus pneumoniae
-
-
0.151
2-chloro-N-(3-cyano-2-thienyl)-5-[(diethylamino)sulfonyl]benzamide
Streptococcus pneumoniae
-
-
0.022
2-chloro-N-(3-cyano-3,4,5,6-tetrahydro-2H-cyclopenta[b]thiophen-2-yl)-5-[(4-hydroxybutyl)sulfamoyl]benzamide
Streptococcus pneumoniae
-
-
0.0000065
2-chloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-4-fluoro-5-(morpholin-4-ylsulfonyl)benzamide
Streptococcus pneumoniae
-
-
0.0000089
2-chloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-5-(morpholin-4-ylsulfonyl)benzamide
Streptococcus pneumoniae
-
-
0.0000079
2-chloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-5-[(diethylamino)sulfonyl]benzamide
Streptococcus pneumoniae
-
-
0.0000151
2-chloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-5-[(methylamino)sulfonyl]benzamide
Streptococcus pneumoniae
-
-
0.0000079
2-chloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)-5-[[(3-hydroxypropyl)amino]sulfonyl]benzamide
Streptococcus pneumoniae
-
-
0.0000617
2-chloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thiophen-2-yl)-4-(methylamino)-5-(morpholin-4-ylsulfonyl)benzamide
Streptococcus pneumoniae
-
-
0.000001 - 0.0000017
2-chloro-N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-5-(morpholin-4-ylsulfonyl)benzamide
0.00000141
2-chloro-N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-(diethylsulfamoyl)benzamide
Streptococcus pneumoniae
-
-
0.0025
2-chloro-N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-(piperidin-1-ylsulfonyl)benzamide
Streptococcus pneumoniae
-
-
0.000003388
2-chloro-N-(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)-5-(diethylsulfamoyl)benzamide
Streptococcus pneumoniae
-
-
0.000004169
2-chloro-N-(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)-5-(morpholin-4-ylsulfonyl)benzamide
Streptococcus pneumoniae
-
-
0.008
2-chloro-N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thien-2-yl)-5-[(diethylamino)sulfonyl]benzamide
Streptococcus pneumoniae
-
-
0.006
2-chloro-N-[3-cyano-5-(2-pyridin-2-ylethyl)thiophen-2-yl]-5-(morpholin-4-ylsulfonyl)benzamide
Streptococcus pneumoniae
-
-
0.000000054
2-chloro-N-[3-cyano-6-(4-hydroxyphenyl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]-5-(diethylsulfamoyl)benzamide
Streptococcus pneumoniae
-
-
0.019
2-thioxo-3-[4-(trifluoromethoxy)phenyl]-2,3-dihydroquinazolin-4(1H)-one
Streptococcus pneumoniae
-
-
0.063
4-[(pentachlorobenzyl)sulfanyl]-6-sulfanyl-1,3,5-triazin-2-ol
Escherichia coli
-
pH 8.0, 37°C
0.078
5-(aminosulfonyl)-2-chloro-N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thien-2-yl)benzamide
Streptococcus pneumoniae
-
-
0.0000257
5-(anilinosulfonyl)-2-chloro-N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thien-2-yl)benzamide
Streptococcus pneumoniae
-
-
0.00000603
ethyl 2-([[2-chloro-5-(diethylsulfamoyl)phenyl]carbonyl]amino)-3-cyano-4,5,6,7-tetrahydro-1-benzothiophene-6-carboxylate
Streptococcus pneumoniae
-
-
0.0075
N-(3-aminopropyl)-4-(trifluoromethyl)-2-([4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]methyl)pyrimidine-5-carboxamide
Escherichia coli
-
-
0.000074
N-(3-cyano-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]thiophen-2-yl)-2-[[3-(dimethylamino)propyl]amino]-5-(morpholin-4-ylsulfonyl)benzamide
Streptococcus pneumoniae
-
-
0.0025
N-(4-carbamimidoylphenyl)-4-(trifluoromethyl)-2-([4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]methyl)pyrimidine-5-carboxamide
Escherichia coli
-
-
0.0126
N-(5-bromo-3-cyano-2-thienyl)-2-chloro-5-[(diethylamino)sulfonyl]benzamide
Streptococcus pneumoniae
-
-
0.0025
N-[3-(cyclopentylamino)propyl]-2-[[4-(4-methylphenyl)-1,3-thiazol-2-yl]amino]-4-(trifluoromethyl)pyrimidine-5-carboxamide
Escherichia coli
-
-
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.006
-
purified recombinant mutant K202A, in presence of butylamine
0.016
-
purified recombinant mutant K202A
0.032
-
purified recombinant mutant K202A, in presence of propylamine
0.04
purified recombinant enzyme, 42°C; purified recombinant murF2 mutant, 42°C
0.046
-
purified recombinant mutant K202A, in presence of ethylamine
0.052
-
purified recombinant mutant K202A, in presence of formate
0.062
purified recombinant enzyme, 30°C; purified recombinant murF2 mutant, 30°C
0.437
-
purified recombinant mutant K202A, in presence of butyrate
0.511
-
purified recombinant mutant K202A, in presence of acetate
0.55
-
purified recombinant wild-type enzyme, in presence of methylamine
0.71
-
purified recombinant wild-type enzyme, in presence of propylamine
0.72
-
purified recombinant wild-type enzyme, in presence of butylamine
0.76
-
purified recombinant wild-type enzyme, in presence of propionate
0.769
-
purified recombinant mutant K202A, in presence of propionate
0.8
-
purified recombinant wild-type enzyme, in presence of ethylamine
0.88
-
purified recombinant wild-type enzyme, in presence of acetate
0.93
-
purified recombinant wild-type enzyme, in presence of formate
1.24
-
purified recombinant wild-type enzyme, in presence of butyrate
1.27
-
purified recombinant wild-type enzyme
11.2
purified recombinant wild-type enzyme, 30°C
13.9
purified recombinant wild-type enzyme, 42°C
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
8.6
-
assay at
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
37
-
assay at
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
PDB
SCOP
CATH
ORGANISM
UNIPROT
Acinetobacter baumannii (strain AB307-0294)
Acinetobacter baumannii (strain AB307-0294)
Escherichia coli (strain K12)
Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)
Q9HVZ7
Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)
Q9HVZ7
Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)
Q9HVZ7
Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Crystallization/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
crystallization of two MurF-ATP complexes: the MurF–ATP complex and the MurF-ATP-UDP complex, trigonal crystals of Se-AbMurF with ATP are grown in a precipitant solution containing 20% w/v PEG 3000 and 0.1 M sodium citrate-citric acid, pH 5.5, crystals of the AbMurF-ATP-UDP complex are obtained by soaking experiments, trigonal crystals of the AbMurF-ATP complex isomorphous to those of the Se-AbMurF-ATP complex are grown in the mother liquor and are then transferred to a solution containing 20% glycerol, 20% PEG 3000, 0.1 M sodium citrate-citric acid, pH 5.5, and 15 mM UDP, 25 min soaking, monoclinic crystals of the AbMurF-ATP complex are grown in a precipitant solution containing 24% PEG 4000, 0.08 M Tris-HCl, pH 8.5, 0.16 M MgCl2, and 20% glycerol by the micro-batch crystallization method at 22°C, X-ray diffraction structure determination and analysis at 1.8-2.8 A resolution
-
purified MurF in complex with ATP, microbatch crystallization method, mixing of 0.002 ml of 15 mg/ml protein in 150 mM NaCl, 20 mM HEPES, pH 7.4, and 1 mM DTT, with 0.002 ml of reservoir solution containing 0.1 M sodium citrate–citric acid pH 5.5, 20% PEG 3000, 22°C, X-ray diffraction structure determination and analysis at 1.90 A resolution
-
hanging-drop vapour diffusion method, purified recombinant enzyme 12.2 mg/ml, in 10 mM Tris-HCl, pH 7.4, 10 mM DTT, plus equal volume of reservoir solution: 0.1 M Bis-Tris propane buffer, pH 9.4, 18% PEG 8000, 0.12 M MgSO4, 10% glycerol, about 20 days, X-ray diffraction structure determination at 2.8 A resolution, and analysis
crystals of MurF with bound inhibitor
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
recombinant from strain BL21(DE3)
recombinant His-tagged enzyme from Escherichia coli strain B834(DE3) by nickel affinity chromatography, gel filtration, and ultrafiltration
recombinant wild-type and mutant enzyme from strain JM83
-
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
expression in Escherichia coli or Streptomyces coelicolor
-
expression in strain BL21(DE3)
expression of naturally occuring mutant allele murF2 with A288T mutation as glutathione S-transferase fusion protein; expression of point mutants, expression of wild-type and naturally occuring mutant allele murF2 with A288T mutation as glutathione S-transferase fusion proteins
gene murF, recombinant expression of His-tagged selenomethionine-substituted enzyme in Escherichia coli strain B834(DE3)
overexpression of wild-type and MurF mutant K202A as His-tagged enzymes in strain JM83
-
ENGINEERING
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
A288T
naturally occuring murF2 allele, expressed as a fusion protein with glutathione S-transferase, is 181fold less catalytically active than the wild-type enzyme at 30°c and even more reduced at 42°C
E158A
site-directed mutagenesis, 4520fold reduced activity compared to the wild-type
E158D
site-directed mutagenesis, 246fold reduced activity compared to the wild-type
E158G
site-directed mutagenesis, over 451fold reduced activity compared to the wild-type
H188A
site-directed mutagenesis, 203fold reduced activity compared to the wild-type
H188D
site-directed mutagenesis, 2990fold reduced activity compared to the wild-type
H188G
site-directed mutagenesis, 214fold reduced activity compared to the wild-type
H188N
site-directed mutagenesis, 1860fold reduced activity compared to the wild-type
K202A
-
site-directed mutagenesis, exchange of highly conserved lysine residue leads to highly reduced activity, activity can be rescued best by addition of propionate or other short-chain carboxylic acids, but only in a small extent by amines
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
drug development
medicine
-
MurF is a potential target for antibacterial design because it is unique to bacteria and performs an essential non-redundant function in the bacterial cell
pharmacology
Show AA Sequence (18985 entries)
Longer loading times are possible. Please use the Sequence Search for a specific query.